Immunic (NASDAQ:IMUX) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Immunic (NASDAQ:IMUX) in a research note published on Tuesday,Benzinga reports. HC Wainwright currently has a $10.00 target price on the stock. HC Wainwright also issued estimates for Immunic’s Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.77) EPS, FY2026 earnings at ($0.74) EPS, FY2027 earnings at ($0.57) EPS, FY2028 earnings at ($0.27) EPS and FY2029 earnings at ($0.06) EPS.

Several other analysts also recently weighed in on the company. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. William Blair started coverage on shares of Immunic in a research report on Tuesday, March 25th. They set an “outperform” rating for the company. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Immunic in a report on Thursday, April 10th. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $13.20.

Immunic Price Performance

Shares of IMUX opened at $0.98 on Tuesday. The company’s fifty day moving average price is $1.08 and its 200-day moving average price is $1.15. Immunic has a 1-year low of $0.83 and a 1-year high of $2.11. The firm has a market capitalization of $88.35 million, a PE ratio of -0.80 and a beta of 1.91.

Institutional Investors Weigh In On Immunic

Hedge funds have recently bought and sold shares of the stock. Invesco Ltd. acquired a new position in shares of Immunic in the 4th quarter valued at $37,000. Virtu Financial LLC purchased a new position in Immunic in the third quarter valued at $50,000. HB Wealth Management LLC purchased a new position in Immunic in the fourth quarter valued at $81,000. Barclays PLC purchased a new stake in shares of Immunic during the 4th quarter worth about $84,000. Finally, Jane Street Group LLC boosted its stake in shares of Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after acquiring an additional 38,553 shares in the last quarter. Hedge funds and other institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.